Earnings summaries and quarterly performance for PMV Pharmaceuticals.
Executive leadership at PMV Pharmaceuticals.
Board of directors at PMV Pharmaceuticals.
Research analysts covering PMV Pharmaceuticals.
Recent press releases and 8-K filings for PMVP.
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
PMVP
Earnings
Guidance Update
New Projects/Investments
- PMV Pharmaceuticals reported $112.9 million in cash, cash equivalents, and marketable securities as of December 31, 2025, providing an expected cash runway to the end of the second quarter of 2027.
- The company plans to submit a New Drug Application (NDA) for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
- Rezatapopt was granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancer.
- Updated data from the PYNNACLE Phase 2 trial in ovarian cancer demonstrated a 50% overall response rate (ORR) among 48 evaluable patients after the September 4, 2025 data cut-off.
7 hours ago
PMV Pharmaceuticals Provides Update on Rezatapopt Phase 2 Data and Regulatory Path
PMVP
Product Launch
New Projects/Investments
Guidance Update
- PMV Pharmaceuticals' lead candidate, rezatapopt, a first-in-class investigational P53 Y220C reactivator, demonstrated compelling interim Phase 2 results in the PYNNACLE study, achieving a 46% overall response rate (ORR) and 8-month median duration of response (DOR) in ovarian cancer, with the ORR reaching 50% post-data cutoff.
- The company plans an NDA submission in Q1 2027 for rezatapopt in platinum-resistant refractory ovarian cancer (PROC), targeting a potential U.S. launch by the end of 2027.
- PMV Pharmaceuticals has a cash runway through Q1 2027.
- The estimated U.S. market potential for rezatapopt in second-line plus ovarian cancer is $350 million-$420 million, with a global potential of $520 million-$630 million.
- Future growth initiatives include label expansion beyond ovarian cancer and exploring combinations with other therapies, such as bevacizumab and pan-KRAS inhibitors.
4 days ago
PMV Pharma Provides Update on Rezatapopt Phase 2 Data and Regulatory Strategy
PMVP
Product Launch
New Projects/Investments
Guidance Update
- PMV Pharma's lead candidate, rezatapopt, a P53 Y220C reactivator, demonstrated compelling interim Phase 2 efficacy, achieving a 46% overall response rate (50% post-data cutoff) and an 8-month median duration of response in ovarian cancer.
- The company plans an NDA submission in Q1 2027 for accelerated approval in the platinum-resistant refractory ovarian cancer patient population, targeting a potential U.S. launch by the end of 2027.
- The estimated U.S. market potential for rezatapopt in second-line plus ovarian cancer is $350 million-$420 million, with a global potential of $520 million-$630 million. PMV Pharma maintains a strong balance sheet with a cash runway through Q1 2027 and is exploring label expansion beyond ovarian cancer and combination therapies for future growth.
4 days ago
PMV Pharmaceuticals Details Rezataopt Phase 2 Efficacy and Q1 2027 NDA Submission Plan
PMVP
New Projects/Investments
Guidance Update
Product Launch
- PMV Pharmaceuticals' lead candidate, rezatapopt, a P53 Y220C reactivator, demonstrated compelling interim Phase 2 efficacy with a 46% overall response rate (ORR) and an 8-month median duration of response (DOR) in ovarian cancer patients. Post-data cutoff, the ORR in ovarian cancer reached 50%.
- The company plans to submit a New Drug Application (NDA) in Q1 2027 for rezatapopt in platinum-resistant refractory ovarian cancer, targeting a potential U.S. launch by the end of 2027 via accelerated approval.
- PMV Pharmaceuticals has a strong balance sheet providing a cash runway through Q1 2027.
- The addressable second-line plus ovarian cancer market for rezatapopt is estimated at $350 million-$420 million in the U.S. and $520 million-$630 million globally.
4 days ago
PMV Pharmaceuticals Announces Publication of Rezatapopt Phase 1 Data in NEJM
PMVP
Product Launch
New Projects/Investments
- PMV Pharmaceuticals announced the publication of Phase 1 results for its drug candidate rezatapopt in the New England Journal of Medicine (NEJM).
- The Phase 1 study, involving 77 patients with advanced solid tumors harboring a TP53 Y220C mutation, demonstrated antitumor activity and established proof-of-concept for p53 reactivation.
- The company plans to submit a New Drug Application (NDA) for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
- Interim Phase 2 data, as of September 4, 2025, showed an overall response rate (ORR) of 34% (35/103 patients) across all cohorts, and 46% (22/48 patients) in the ovarian cancer cohort.
Feb 26, 2026, 1:00 PM
PMV Pharmaceuticals Reports Q3 2025 Financial Results and Positive Clinical Data
PMVP
Earnings
Guidance Update
New Projects/Investments
- PMV Pharmaceuticals, Inc. reported $129.3 million in cash, cash equivalents, and marketable securities as of September 30, 2025, providing an expected cash runway to the end of the first quarter of 2027.
- The company announced updated clinical results from the Phase 2 pivotal portion of the PYNNACLE study for rezatapopt, observing a 34% overall response rate (ORR) among 103 evaluable patients across all cohorts, with a median duration of response of 7.6 months.
- In the ovarian cancer cohort, a 46% ORR was observed among 48 evaluable patients, with a median duration of response of 8.0 months.
- PMV Pharma plans to submit a New Drug Application (NDA) for rezatapopt for platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
Nov 12, 2025, 1:00 PM
PMV Pharmaceuticals Announces Updated Rezatapopt Phase 2 Clinical Trial Data
PMVP
New Projects/Investments
Product Launch
- PMV Pharmaceuticals reported updated interim data from its Phase 2 PYNNACLE clinical trial for rezatapopt, showing a 34% overall response rate (ORR) among 103 evaluable patients across all cohorts, with a median duration of response of 7.6 months.
- In the ovarian cancer cohort, rezatapopt achieved a 46% ORR among 48 evaluable patients, with a median duration of response of 8.0 months.
- The company plans to submit a New Drug Application (NDA) for rezatapopt for platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
- Treatment-related adverse events were mostly Grade 1-2, with a drug discontinuation rate of 3.6% due to TRAEs.
Oct 24, 2025, 3:39 PM
PMV Pharmaceuticals Provides Update on Rezatapopt Clinical Program and Financial Outlook
PMVP
New Projects/Investments
Guidance Update
- PMV Pharmaceuticals (PMVP) reported that its clinical candidate, rezatapopt, achieved a 38% Overall Response Rate (ORR) at the recommended Phase II dose of 2,000 mg q.d. in its Phase I trial.
- An interim analysis for the single-arm registrational Phase II trial of rezatapopt is expected in the middle of 2025, with the company targeting an NDA submission by the end of 2026.
- The company ended 2024 with a cash balance of $183 million, which is expected to fund operations through the end of 2026.
- PMV Pharmaceuticals has also initiated a Phase Ib combination study of rezatapopt in AML and anticipates announcing a development candidate for an undisclosed target in mid-2025.
Mar 4, 2025, 8:10 PM
PMV Pharmaceuticals Provides Update on Rezatapopt Phase II Trial and Financial Runway
PMVP
Guidance Update
New Projects/Investments
- PMV Pharmaceuticals had planned an interim analysis in mid-2025 for its pivotal Phase II trial of rezatapopt, a p53 reactivator, which was to include a minimum of 30 patients and 18 weeks of follow-up.
- The company aims to submit a New Drug Application (NDA) for rezatapopt by the end of 2026, targeting an accelerated approval strategy based on a 30% overall response rate and six months median durability of response.
- PMV Pharmaceuticals reported a cash balance of $183 million at the end of 2024, which is projected to fund operations through the end of 2026.
- The Phase II study is a basket study of 114 patients with TP53 Y220C and KRAS wild-type solid tumors, with 42 patients in ovarian cancer and 18 patients each in lung, breast, endometrial, and other solid tumor cohorts.
- PMV had also planned to provide information on a new, undisclosed, orally administered, non-covalent development candidate for solid tumors, orthogonally connected to p53, in mid-2025, with an IND submission targeted for H1 2026.
Mar 4, 2025, 8:10 PM
PMV Pharma Provides Update on Rezatapopt Phase 2 Trial and Pipeline Development
PMVP
New Projects/Investments
Guidance Update
- PMV Pharma's lead product, Rezatapopt, is in a phase two registrational trial for mutant p53s, with interim data expected mid-2025. The company plans to share data from at least 30 patients with 18 weeks of follow-up across all study cohorts.
- The phase two study is designed to target a 30% overall response rate (ORR), building on phase one data that showed a 38% confirmed ORR at 2,000 mg QD with food, including a 47% response rate in ovarian cancer and a seven-month median duration of response.
- An initial NDA submission for Rezatapopt, likely starting with ovarian cancer, is anticipated by the end of 2026.
- The company reported $198 million in cash at the end of the third quarter (last year), providing a runway through the end of 2026, and is exploring options to raise additional capital.
- PMV Pharma plans to announce a new program in the development candidate phase in Q2 2025, with IND-enabling studies to follow and a potential first-in-human trial in 2026 for a target related to the p53 pathway.
Feb 12, 2025, 5:40 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more